Synta Pharmaceuticals Corp. (NASDAQ:SNTA)
CAPS Rating:
A biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs that address severe medical conditions with potential markets, including cancer and chronic inflammatory diseases.
RSS Headlines
Fool UK
Recs
Many Phase II and one Phase III ongoing on multiple small molecule drugs against cancer and inflammatory disease. Harvard/MIT scientists. Promising data.